Age, Biography and Wiki
David Grainger was born on 12 October, 1966, is a David Grainger is partner at medicxi. Discover David Grainger's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 57 years old?
| Popular As |
N/A |
| Occupation |
venture capitalist, medicxi, biotechnology executive, Methuselah Health Ltd., blogger |
| Age |
57 years old |
| Zodiac Sign |
Libra |
| Born |
12 October, 1966 |
| Birthday |
12 October |
| Birthplace |
N/A |
| Nationality |
|
We recommend you to check the complete list of Famous People born on 12 October.
He is a member of famous executive with the age 57 years old group.
David Grainger Height, Weight & Measurements
At 57 years old, David Grainger height not available right now. We will update David Grainger's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
David Grainger Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is David Grainger worth at the age of 57 years old? David Grainger’s income source is mostly from being a successful executive. He is from . We have estimated David Grainger's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
executive |
David Grainger Social Network
Timeline
David Grainger is a partner at medicxi, a European life sciences-oriented venture capital firm and chief executive officer of Methuselah Health Ltd., a drug development company doing proteomics research in the longevity space.
He was formerly with Index Ventures, an international venture capital firm with offices in London, Geneva and San Francisco, in the firm's life sciences practice.
He also writes for Forbes.com on topics related to the pharmaceutical industry.
Reared in England, Grainger graduated with degree in Natural Sciences (Biochemistry) from Cambridge University in 1989, and a PhD in Vascular Cell Biology from the same institution in 1992.
After receiving his PhD, Grainger undertook post-doctoral research in the British Heart Foundation Smooth Muscle Cell laboratory at Cambridge University.
Following publications in Nature and elsewhere setting out his Protective Cytokine Hypothesis explaining the role of the cytokine TGF-beta 1 in the cardiovascular system, Grainger was appointed principal investigator in the Department of Medicine at his alma mater, Cambridge University, in 1997.
While at Cambridge University, Grainger founded life sciences companies including FingerPrint Diagnostics (2001), and Funxional Therapeutics (2005).
FingerPrint Diagnostics merged with SmartBead Technologies to form Pronostics, a molecular diagnostics company, in 2006.
Funxional Therapeutics, based on an anti-inflammatory drug candidate spun-out from Grainger's Cambridge University lab, became an Index Ventures portfolio company where Grainger also served as chief scientific officer until it was sold to Boehringer Ingelheim in 2012.
Grainger joined Index Ventures in 2012, and a blogger on topics related to the pharmaceutical industry under the pen name “DrugBaron”.
where he was involved with funding and advising a variety of companies, including XO1, a biotech company developing an anticoagulant, where he served as chairman and interim CEO before it was sold to Johnson & Johnson He co-founded medicxi in February 2016 with fellow former Index Ventures partners Francesco De Rubertis, Kevin Johnson and Michele Ollier.
Grainger has co-authored a number of papers in peer-reviewed scientific journals, including Nature, Science and Nature Medicine.
Grainger formerly blogged under the pen name “DrugBaron” on a range of topics related to the pharmaceutical industry, and now has a column on similar topics on Forbes.com.
